Human-Centered Design in AI-Driven Clinical Decision Making

By Sumona Bose

February 6, 2024

Introduction

Artificial intelligence (AI) technologies have revolutionized the healthcare industry, particularly in the realm of clinical decision support systems (CDSS). These AI-empowered systems provide patient-specific recommendations to improve clinical work. However, alongside technical advancements, it is crucial to consider the human, social, and contextual factors that impact the successful implementation and user adoption of AI-CDSS. Human-centered design plays a pivotal role in ensuring the effectiveness and acceptance of these systems. Human centered design in AI has been an important research avenue.

The Role of AI in Clinical Decision Making

AI-empowered CDSS has shown great promise in enhancing patient evaluation and work efficiency. By analyzing vast amounts of data, AI algorithms can identify patterns and provide clinicians with valuable insights for making informed decisions. This technology has the potential to revolutionize healthcare by improving diagnostic accuracy, treatment planning, and patient outcomes.

Understanding User Needs and Experiences

To gain a comprehensive understanding of AI-CDSS, a systematic review was conducted, analyzing 20 relevant articles published between 2011 and 2022. The studies assessed various aspects of AI-CDSS, including effectiveness, user needs, user experience, and other dimensions.

The effectiveness of AI-CDSS was demonstrated through improved patient evaluation and work efficiency. Clinicians reported that AI recommendations helped them make more accurate diagnoses and develop personalized treatment plans. This technology has the potential to significantly enhance clinical decision-making processes.

User needs and experiences were also explored in the reviewed studies. Clinicians expressed the importance of having access to relevant and timely information, as well as the need for user-friendly interfaces. Additionally, factors such as satisfaction, trust, usability, workload, and understandability were found to influence the acceptance and adoption of AI-CDSS.

www.frontiersin.org
Figure 1: System features and examples.

Challenges in Implementing AI-CDSS

Despite the promising nature of AI-CDSS, the systematic review identified several challenges in implementing these systems. Technical limitations, such as algorithmic biases and data quality issues, can hinder the accuracy and reliability of AI recommendations. Workflow misalignment, attitudinal barriers, and informational barriers were also identified as challenges that impact the effective use of AI-CDSS in clinical settings.

Conclusion

The integration of artificial intelligence in clinical decision-making processes holds great potential for improving patient outcomes and work efficiency. However, the successful implementation of AI-empowered clinical decision support systems requires careful consideration of human-centered design principles and addressing the challenges identified in this study. By prioritizing user needs and experiences, healthcare professionals can harness the full benefits of AI technology in healthcare.

Reference url

Recent Posts

NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
EU Medical Device Panels: Enhancing Safety and Performance Evaluations EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluat...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...